Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene (EVGN) selected acute graft-versus-host disease as the target indication for its internal AI-driven small-molecule drug discovery program.
The program targets severe inflammation in patients who do not respond to steroids after blood-forming stem cell transplantation. In several months, Evogene has begun generating novel small-molecule candidates using its ChemPass AI platform. The candidates show potency at nanomolar concentrations, target selectivity, and favorable absorption, distribution, metabolism, excretion and toxicology profiles. Evogene plans to advance its lead candidates toward IND-enabling studies, studies supporting an application to begin human testing.
Evogene (EVGN) will attend BIO-Europe in Cologne, Germany, and present a scientific poster at Drug Discovery Chemistry Europe in Barcelona, Spain.
BIO-Europe runs November 9–11, 2026. Chief Development Officer Dr. Gabi Tarcic will represent Evogene and be available for one-on-one meetings with potential partners about AI-driven small-molecule discovery and development. Drug Discovery Chemistry Europe runs November 10–12, 2026. Executives involved in developing Evogene's technology platform will attend, and the poster will showcase its ChemPass AI small-molecule discovery platform.
Evogene (NASDAQ: EVGN; TASE: EVGN) will participate in the AI Drug Discovery Roadshow across the U.S. East Coast on November 2-5, 2026.
Organized by the Israel Export Institute and TradeIL, the roadshow will include New York, New Jersey, Philadelphia, Washington, D.C., and Maryland. President and CEO Ofer Haviv will present ChemPass AI, the company's platform for discovering and optimizing small molecules, and be available for investor and partner meetings.
Evogene (EVGN) entered into a cooperation agreement with Pure Capital Group that provides for changes to its board of directors.
A shareholder meeting will be held within 42 days following execution to elect nominees and approve the agreement. Following shareholder approval, the board will comprise seven directors: four Pure Capital Group nominees and three continuing directors. Pure Capital Group comprises L.I.A. Pure Capital and Invest Pro Shukai Hon.
Pure Capital Group agreed to withdraw its special tender offer notice and enter a 60-day standstill. During that period, Evogene agreed not to issue shares or convertible securities, except ordinary-course employee issuances consistent with prior practice.
Evogene (EVGN) received an additional 180-day period from Nasdaq to regain compliance with its minimum bid price requirement by March 29, 2027. The initial deadline was September 28, 2026, following a March 30 notice that its closing bid price had been below $1.00 for 30 consecutive business days.
Compliance requires a closing bid price of at least $1.00 for at least ten consecutive business days. Failure to meet listing requirements by the extended deadline would trigger a delisting notification. Evogene intends to consider alternatives, potentially including a reverse share split, if the deficiency persists. The letter has no immediate effect on Nasdaq trading and no bearing on its Tel Aviv Stock Exchange listing.
Evogene (NASDAQ: EVGN) outlined a broad operational and financial transformation ahead of its September 4, 2026 Annual General Meeting, where shareholders are asked to vote for the company’s director nominees. According to Evogene, over the last 18 months it has repositioned itself around its ChemPass AI™ computational chemistry platform, developed with autonomous AI agents in collaboration with Google Cloud.
The company reports six drug-development agreements with biotechnology companies and academic institutions, indicating external use of ChemPass AI™ via partnerships. Evogene states it has reduced annual cash burn from about $20.5 million in 2024 to an expected $8.5–$9.5 million in 2026, cut headcount from 117 to 38 employees, raised $11.1 million in new capital, monetized Lavie Bio for approximately $15.25 million through a sale to ICL, licensed Biomica’s Phase I asset to Lishan Biotech, and refocused Casterra on Brazil’s sustainable aviation fuel market. The company is also refreshing its Board with proposed additions of Dr. Yael Margolin and Mr. Yoshinori Oikawa.
Evogene (NASDAQ/TASE: EVGN) reported first-half 2026 and Q2 2026 results, highlighting its shift to an AI-driven computational chemistry focus for pharma and crop protection. Q2 net loss narrowed to approximately $1.8 million versus $4.7 million in Q2 2025, while first-half net loss remained about $7.7 million year over year.
The company cut its workforce from 117 employees in December 2024 to 38 in August 2026 and expects 2026 cash usage of roughly $8.5–$9.5 million, down from about $14.4 million in 2025 and $20.5 million in 2024. As of June 30, 2026, cash and cash equivalents were approximately $9.3 million, with Q2 cash usage of about $2.1 million.
Revenues fell to roughly $0.7 million in H1 2026 from $2.9 million a year earlier, mainly due to lower Casterra revenues and the end of AgPlenus’ Bayer agreement. Evogene reported six active drug collaborations and expanded its ChemPass AI™ virtual chemical space to about 110 billion molecules. Dividends from Lavie Bio and Biomica totaled approximately $4.25 million to Evogene since 2025.
Evogene (Nasdaq: EVGN) announced that Chairman Nir Nimrodi will participate in the company’s upcoming quarterly results Zoom conference call on Tuesday, August 18, 2026, at 9:00 AM Eastern Time (4:00 PM Israel time). The call will be accessible via advance online registration and a replay will be posted on Evogene’s website.
Evogene (Nasdaq: EVGN) will release its second quarter 2026 financial results on Tuesday, August 18, 2026. The company, which focuses on computational chemistry and generative design of small molecules for pharma and agriculture, will hold a management-hosted Zoom conference call that same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results.
Investors must register in advance via the provided Veidan Conferencing link, and a replay of the entire conference will be available on Evogene's website a few days after the event.
Evogene (Nasdaq: EVGN) and ELEO announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors of the PCSK9 pathway for treating hyperlipidemia and cardiovascular diseases. The collaboration combines Evogene's ChemPass AI™ computational chemistry platform with ELEO's biological capabilities, including target validation, PCSK9 expression suppression models, and screening platforms.
The partners aim to generate, optimize, and experimentally validate novel candidates with improved oral potency, bioavailability, selectivity, and drug-like properties, accelerating advancement toward preclinical development. According to the companies, this targets a PCSK9 inhibitor market projected to grow from about $4.4 billion in 2025 to over $23 billion by 2035, and may support future strategic licensing, clinical development, or pharmaceutical partnerships.